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Abstract Hepatocyte growth factor activator inhibitor type 2
(HAI-2) was identified as a potent inhibitor of hepatocyte growth
factor activator (HGF activator). The primary translation
product of HAI-2 contains two Kunitz domains. To characterize
their function, we introduced a point mutation into the reactive
site of each Kunitz domain, and assayed the mutants for their
HGF activator inhibitory activity. A point mutation in the
COOH-terminal Kunitz domain did not affect the activity of
HAI-2, whereas a point mutation in the NH2-terminal Kunitz
domain markedly reduced the activity. These results suggest that
the NH2-terminal Kunitz domain is mainly responsible for the
HGF activator inhibitory activity of HAI-2.
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1. Introduction
Two Kunitz-type serine protease inhibitors, that e⁄ciently
suppress the proteolytic activity of hepatocyte growth factor
activator (HGF activator) in vitro, were isolated from the
conditioned medium of a human stomach carcinoma cell
line, and designated HGF activator inhibitor type 1 and
type 2 (HAI-1 and HAI-2) [1,2]. HGF activator is a serine
protease that converts the inactive single-chain precursor of
HGF to the active heterodimer in response to tissue injury [3^
5]. The proteolytically activated HGF may be involved in
regeneration of the injured tissues [6^8]. Thus, HGF activator
is a speci¢c enzyme that regulates the activity of HGF in
injured tissues. Because HAIs are potent inhibitors of HGF
activator, they may be involved in regulating the activity of
HGF by suppressing the HGF-converting activity of HGF
activator.
Recently, cDNA cloning of two Kunitz-type serine protease
inhibitors was reported [9,10]. A cDNA clone was isolated
from a human placenta cDNA library using the consensus
sequence of Kunitz domains obtained from the expressed se-
quence tag data base. A protein which is encoded by the
cDNA was puri¢ed from human placenta, and named placen-
tal bikunin. The puri¢ed protein exhibited potent inhibitory
activity against trypsin, plasma kallikrein and plasmin [9].
Another cDNA clone was isolated by a large scale screen
for di¡erentially expressed genes in pancreatic cancer. North-
ern blot analysis using the isolated cDNA as a probe showed
that the gene named kop was highly overexpressed in pancre-
atic cancer cell lines and in pancreatic cancer tissues [10].
Comparison of the cDNA sequences of HAI-2, placental bi-
kunin and the kop product revealed that all three proteins are
identical.
The primary translation product of HAI-2, which was de-
duced from the cDNA sequence, consists of 252 amino acids
with a calculated molecular mass of 28 kDa including an
NH2-terminal signal peptide sequence of 27 amino acids [2].
It contains two Kunitz domains and a COOH-terminal hydro-
phobic region of 24 amino acids. This characteristic structure
suggests that HAI-2 is ¢rst produced in a membrane associ-
ated form and then secreted from producing cells in a COOH-
terminally truncated form by proteolytic processing. Because
HAI-2 has two Kunitz domains, it is important to elucidate
which Kunitz domain is responsible for the inhibitory activity
of HAI-2 against HGF activator. We thus constructed
cDNAs encoding HAI-2 proteins which have a point muta-
tion in a putative reactive site of each Kunitz domain. The
cDNAs were stably transfected into Chinese hamster ovary
(CHO) cells, and expressed proteins were assayed for the in-
hibitory activity against the HGF-converting activity of HGF
activator. A protein with a mutation in the COOH-terminal
Kunitz domain (Kunitz II) had comparable activity with the
wild-type protein, whereas a protein with a mutation in the
NH2-terminal Kunitz domain (Kunitz I) had much weaker
activity than the wild-type protein. These results suggest
that the NH2-terminal Kunitz domain is mainly responsible
for the inhibitory activity of HAI-2 against HGF activator.
2. Materials and methods
2.1. Construction of expression plasmids for HAI-2 mutant cDNAs
A cDNA encoding a secreted form of HAI-2 (sHAI-2) was con-
structed by polymerase chain reaction (PCR) using the full length
HAI-2 cDNA as a template and two oligonucleotide primers, 5P-
GAGTCGACCATGGCGCAGCTGT-3P and 5P-CCCTGCAGCTG-
GCGGAAGCAGC-3P. The PCR product was digested with SalI
and PstI and inserted into the XhoI and PstI sites of an expression
plasmid vector pME18S [11]. A cDNA encoding a mutant HAI-2
which had a point mutation (R48L) in Kunitz I was constructed
with a Quick change site-directed mutagenesis kit (Stratagene) using
pME18S-sHAI-2 as a template and two oligonucleotide primers, 5P-
GTGGGCAGATGCCTGGCCTCCATGCC-3P and 5P-GGCATG-
GAGGCCAGGCATCTGCCCAC-3P. A cDNA encoding a mutant
HAI-2 which had a point mutation (R143L) in Kunitz II was con-
structed with the same kit using pME18S-sHAI-2 as a template and
two oligonucleotide primers, 5P-CACTGGGCCTTGCCTTGCATC-
CTTCCC-3P and 5P-GGGAAGGATGCAAGGCAAGGCCCAGT-
G-3P. A cDNA encoding a mutant HAI-2 which had point mutations
(R48L and R143L) in both Kunitz domains was also constructed with
this kit using pME18S-sHAI-2 (R48L) as a template and the two
oligonucleotide primers used for construction of pME18S-sHAI-2
(R143L).
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2.2. Expression of plasmids for HAI-2 mutant cDNAs in CHO cells
CHO cells were cultured in a 60-mm culture dish in a 1:1 mixture
of DMEM and Ham’s F12 medium containing 10% fetal bovine se-
rum (FBS). At 60V80% con£uence, 5 Wg of each expression plasmid
and 0.5 Wg of pRSVneo were cotransfected into CHO cells by the
lipofectoamine method [12]. After transfection, the cells were cultured
in the medium containing 0.5 mg/ml of G418 and 10% FBS. G418-
resistant colonies were selected and screened for expression of the
mutant HAI-2 proteins by immunoblotting.
2.3. Preparation of a polyclonal antibody against bacterially expressed
HAI-2
The HAI-2 cDNA was digested with BamHI and StuI (nucleotide
residues 181-534), and inserted into the BamHI and SmaI sites of a
plasmid vector pGEX-4T-2 (Pharmacia). A fusion protein with gluta-
thione-S-transferase was expressed in Escherichia coli. After sonica-
tion, cell lysate was recovered by centrifugation at 45 000Ug and the
fusion protein was bound to glutathione-Sepharose 4B beads (Phar-
macia). After the Sepharose beads had been washed three times with
phosphate bu¡ered saline (PBS) containing 0.3 M NaCl, the fusion
protein was eluted with PBS containing 5 mM glutathione. Rabbits
were immunized with the puri¢ed fusion protein, and antiserum (anti-
HAI-2) was raised.
2.4. Immunoblotting analysis of HAI-2 mutant proteins
Each CHO cell line that stably expressed HAI-2 mutant proteins
was cultured in a 150-mm culture dish in the medium containing 10%
FBS. At con£uence, the medium was replaced with 25 ml of serum-
free medium. After 50 h, the conditioned medium was harvested and
concentrated to 0.5 ml. Fifty Wl of the concentrated sample was sep-
arated by SDS-PAGE (15% polyacrylamide) under reducing condi-
tions. The proteins were transferred to a nitrocellulose membrane
(Hybond ECL; Amersham), and incubated with the anti-HAI-2 anti-
serum for 3 h. This was followed by incubation with horseradish
peroxidase-conjugated secondary antibodies for 1 h. Immunoreactive
proteins were visualized with the enhanced chemiluminescence immu-
noblotting detection system (Amersham).
2.5. Assay for HGF activator inhibitory activity of HAI-2 mutant
proteins
The concentration of the mutant proteins in the conditioned me-
dium was determined by immunoblotting analysis. Five Wl of HGF
activator (0.3 ng/Wl) was mixed with various concentrations of the
mutant proteins in 40 Wl of PBS containing 0.05% CHAPS and in-
cubated at 37‡C for 30 min. Five Wl of single chain HGF (1.6 Wg/Wl)
was added to the mixture which was further incubated for 14 h. After
incubation, HGF was bound to SP-Sepharose beads. After the Se-
pharose beads had been washed three times with PBS, HGF was
eluted with 50 Wl of 250 mM Tris-HCl (pH 6.8) containing 10%
mercaptoethanol, 4% SDS, 20% glycerol and 0.004% bromophenol
blue and separated by SDS-PAGE (12.5% polyacrylamide) under re-
ducing conditions. The gel was stained with Coomassie Brilliant Blue,
and the bands were scanned using a Flying-Spot Scanner CS-9000
(Shimadzu). The inhibitory activity was estimated by calculating the
ratio of the remaining single chain form to total HGF.
3. Results
3.1. Construction and expression of HAI-2 mutant cDNAs
The primary translation product of HAI-2 has a hydropho-
bic sequence at the COOH-terminal region (Fig. 1A), suggest-
ing that the secreted form of HAI-2 obtained from the con-
ditioned medium is generated by proteolytic processing of a
membrane associated form [2]. Thus, it is possible that large
amounts of HAI-2 protein remain in cells in the membrane
associated form. To obtain enough mutant protein in condi-
tioned medium, we ¢rst constructed a cDNA encoding a de-
letion mutant that lacked the hydrophobic sequence. For con-
struction of the deletion mutant, the cDNA sequence
corresponding to the COOH-terminal end of Kunitz II was
fused to the vector sequence, generating a truncated form of
HAI-2 with an additional 9 amino acid sequence derived from
the vector sequence (Fig. 1A). This construct was transfected
into CHO cells, and a cell clone which stably expressed the
secreted form of HAI-2 (sHAI-2) was obtained. Immunoblot-
ting analysis revealed that a HAI-2 protein with a molecular
mass of 25 kDa was secreted in the conditioned medium (Fig.
2, lane 2). Because the molecular mass was larger than that
(19 kDa) predicted from the amino acid sequence of the trun-
cated HAI-2, the secreted HAI-2 protein probably contained
the whole amino acid sequence including Kunitz I and II.
Thus, this cDNA was used to construct HAI-2 mutants
with point mutations in the Kunitz domains. The larger mo-
lecular mass may be due to glycosylation of the protein, be-
cause the HAI-2 protein puri¢ed from the conditioned me-
dium of MKN45 cells was highly glycosylated [2]. The
amino acid residues in the P1 positions of the reactive sites
of various Kunitz domains were assigned as essential for in-
hibitory activity [13,14]. Thus, each arginine residue (Arg48 or
Arg143) in the corresponding position of each Kunitz domain
in HAI-2 (Fig. 1B) was individually changed to a leucine
residue. A cDNA encoding a HAI-2 mutant in which both
the arginine residues were changed to leucine residues was
also constructed. CHO cell lines which stably produced and
secreted each mutant protein were obtained. Immunoblotting
analysis showed that enough mutant protein with the same
molecular mass as the wild type, 25 kDa, was obtained in the
conditioned medium (Fig. 2, lane 3^5). These proteins were
assayed for HGF activator inhibitory activity.
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Fig. 1. A schematic of the structure of the primary translation prod-
uct of HAI-2 (A) and amino acid sequences of the Kunitz domains
in HAI-2 (B). In A, the truncated site used to produce a secreted
form of HAI-2 is indicated by an arrow. In B, putative reactive sites
are indicated by arrows. The conserved cysteine residues are shown
in bold.
Fig. 2. Immunoblotting analysis of mutant HAI-2 proteins. Proteins
in the conditioned medium of each CHO cell clone were separated
by SDS-PAGE (15% polyacrylamide) and transferred to a nitrocel-
lulose membrane. The membrane was incubated with anti-HAI-2
antiserum and developed with peroxidase-conjugated secondary anti-
bodies. Lane 1: Parental CHO cells; lane 2: sHAI-2; lane 3: sHAI-
2 (R48L); lane 4: sHAI-2 (R143L); lane 5: sHAI-2 (R48L/R143L).
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3.2. Assay for HGF activator inhibitory activity of HAI-2
mutant proteins
Fig. 3 shows the dose dependence of the inhibitory activity
of the mutant proteins. HGF activator was mixed with vari-
ous concentrations of the mutant proteins and incubated for
30 min to form an enzyme-inhibitor complex. Single chain
HGF was then added and further incubated. The mixture
was analyzed by SDS-PAGE (Fig. 3A). The inhibitory activity
of mutant proteins was determined as the ratio of the remain-
ing single chain HGF to total HGF and plotted against pro-
tein concentrations (Fig. 3B). A mutation in Kunitz II
(R143L) did not a¡ect the inhibitory activity of HAI-2,
when compared with the wild type. On the other hand, a
mutation in Kunitz I (R48L) markedly reduced the activity
of HAI-2. The concentration of the R143L protein for 50%
inhibition was 80 ng/ml, whereas that of the R48L protein was
1.6 Wg/ml. Thus, the R48L protein was 1/20 less potent than
the R143L protein. No activity was observed in the protein
with point mutations in both Kunitz domains (R48L/R143L).
4. Discussion
The amino acid residues in the P1 positions of the reactive
sites of Kunitz domains were assigned as essential for the
inhibitory activity against serine proteases [13,14]. Both Ku-
nitz domains in HAI-2 have arginine residues in the corre-
sponding positions [2]. Further, the site of cleavage by HGF
activator to generate the active heterodimeric form of HGF is
an arginine residue [15]. Thus, these arginine residues in the
Kunitz domains were expected to function as reactive sites for
the inhibitory activity of HAI-2 against HGF activator. The
HAI-2 protein with replacement of these arginine residues by
leucine residues completely lost the inhibitory activity. The
HAI-2 proteins with replacement of each arginine residue by
a leucine residue retained the inhibitory activity, although the
potency of activity of the protein with a mutation in Kunitz I
was much lower than that with a mutation in Kunitz II. These
results indicate that the arginine residue is essential for the
inhibitory activity of each Kunitz domain of HAI-2 against
HGF activator.
The HAI-2 mutant with the intact Kunitz I and inactive
Kunitz II had potency of inhibitory activity similar to the
wild type, whereas the mutant with the inactive Kunitz I
and intact Kunitz II exhibited much less activity than the
wild type. These results suggest that the NH2-terminal Kunitz
domain (Kunitz I) is mainly responsible for the inhibitory
activity of HAI-2 against HGF activator. Delaria et al. [16]
reported that placental bikunin, identical to HAI-2, inhibited
trypsin, plasma kallikrein, tissue kallikrein and plasmin. They
also reported that the chemically synthesized COOH-terminal
Kunitz domain of placental bikunin exhibited potent inhibi-
tory activity against these serine proteases similar to the syn-
thesized NH2-terminal Kunitz domain [16]. Thus, the COOH-
terminal Kunitz domain (Kunitz II) in HAI-2 may be respon-
sible for inhibiting serine proteases other than HGF activator.
Hepatocyte growth factor activator inhibitor type 1 (HAI-1)
obtained from the conditioned medium of MKN45 cells was
also a COOH-terminally truncated form which appeared to be
generated from the membrane associated form of the primary
translation product [1]. The primary translation product of
HAI-1 contains two Kunitz domains, and the HAI-1 protein
in the conditioned medium of MKN45 cells probably contains
only the NH2-terminal Kunitz domain [1]. The identity of the
amino acid sequences is 54% between the NH2-terminal Ku-
nitz domains in HAI-1 and HAI-2, whereas it is only 41%
between the two Kunitz domains in HAI-2. We previously
examined the HGF activator inhibitory activity of L-amyloid
precursor protein (APP), tissue factor pathway inhibitor
(TFPI) and inter-K-trypsin inhibitor (IKTI) which have Ku-
nitz domains responsible for the inhibitory activities of these
proteins against serine proteases [17^19]. The HGF activator
inhibitory activities of APP and TFPI were very weak, and
that of IKTI was not detected [2]. The identity of the amino
acid sequences is less than 40% between each Kunitz domain
in these proteins and Kunitz I in HAI-2. These ¢ndings sug-
gest that some of the di¡erent amino acid residues contribute
to distinct substrate speci¢city of each Kunitz domain.
IKTI is a high molecular weight glycoprotein with two tan-
demly repeated Kunitz domains in the light chain, which is
one of three polypeptide chains linked by a glycosaminogly-
can [19]. A protease inhibitor, which consists of only the
COOH-terminal Kunitz domain in the light chain of IKTI
[20], has been identi¢ed from mast cells [21]. This inhibitor,
named trypstatin, inhibits factor Xa, tryptase, trypsin and
chymase. Thus, in the case of IKTI, there is a proteolytic
processing pathway to generate an inhibitor with only the
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Fig. 3. Dose dependence of the inhibitory activity of mutant HAI-2
proteins against HGF activator. Various concentrations of the mu-
tant proteins were incubated with HGF activator. After incubation
at 37‡C for 30 min, single chain HGF (scHGF) was added and fur-
ther incubated. The reaction products were subjected to SDS-PAGE
and stained with Coomassie Brilliant Blue (A). The inhibitory activ-
ity was determined as the ratio of the remaining single-chain HGF
to total HGF and plotted against protein concentration (B). sc, hc
and lc indicate the single chain, heavy chain and light chain of
HGF, respectively.
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COOH-terminal Kunitz domain. The secreted form of HAI-2
which was puri¢ed from the conditioned medium of MKN45
cells as an inhibitor against HGF activator is a proteolytically
processed product of the putative membrane associated form.
This processing appears to occur within Kunitz II of HAI-2
[2]. Like the pathway producing trypstatin, there may be an-
other proteolytic processing pathway to produce an inhibitor
with only Kunitz II of HAI-2 which inhibits serine proteases
other than HGF activator. Thus, further characterization of
proteolytic processing pathways of HAI-2 is required to
understand in vivo functions of each Kunitz domain in
HAI-2.
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